PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation
- 15 July 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (14) , 5153-5157
- https://doi.org/10.1158/1078-0432.ccr-05-0397
Abstract
Purpose: Inactivation of the tumor suppressor gene, phosphatase and tensin homologue (PTEN), is a major alteration in preclinical melanoma models. We investigated the clinical relevance of PTEN expression in the primary melanoma patients with extended follow-up.Experimental Design: We correlated PTEN expression with clinicopathologic variables and outcome in 127 primary melanomas (median follow-up, 12.8 years). We evaluated the associations between PTEN expression and proliferation and resistance to apoptosis (assessed by Ki-67 and Bcl-2, respectively). We also examined the effect of a favorable phenotype, defined as retained PTEN, low proliferative index, and low expression of Bcl-2 on disease-free survival and overall survival.Results: Altered PTEN, Bcl-2, and Ki-67 expressions were observed in 55 of 127 (43.3%), 61 of 127 (48%), and 43 of 114 (37.7%) of cases, respectively. Decreased PTEN expression correlated significantly with the ulceration (P = 0.01). Rates of disease-free survival and overall survival in patients with favorable phenotype were 72% and 74% at 5 years versus 64% and 64% in patients with an unfavorable phenotype. At 10 years, the rates of disease-free survival and overall survival were 72% and 68% for patients with a favorable phenotype but declined to 60% and 55% in patients with an unfavorable phenotype. However, relationships between both PTEN and Bcl2 and patient survival were not significant as well as the associations between PTEN and Bcl-2 or Ki-67.Conclusions: Our data suggest that altered PTEN expression is common in primary melanomas and is associated with aggressive tumor behavior. However, PTEN alone provided limited prognostic value. Our findings show the need to examine molecular alterations identified in preclinical studies using an adequately large cohort of patients with extended follow-up to better assess the magnitude of their clinical relevance.Keywords
This publication has 25 references indexed in Scilit:
- Abnormalities in the NF‐κB family and related proteins in endometrial carcinomaThe Journal of Pathology, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiationCancer Gene Therapy, 2004
- PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanomaJournal of the American Academy of Dermatology, 2003
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003
- Evaluation of the proliferation marker MIB‐1 in the prognosis of cutaneous malignant melanomaCancer, 2002
- PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathwayOncogene, 2002
- p53 mediates Bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathwayOncogene, 2000
- Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell linesOncogene, 1998
- MIB-1 Proliferative Activity Is a Significant Prognostic Factor in Primary Thick Cutaneous MelanomasJournal of Investigative Dermatology, 1995